CoChat

Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons

Open access
Meer, Elana A, Oh, Dennis H, Brodie, Frank L · 2022 · Clinical Ophthalmology

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Purpose: To evaluate the holistic cost of longer acting anti-VEGF therapy for macular degeneration when considering the associated costs of travel to the retina clinic. Design: Theoretical evaluation of cost using publicly available pricing data and reimbursements at the Veterans Affairs (VA) Medical Center. Patients and Methods: Setting: VA Medical Center. Study population: Patients with age related macular degeneration. Main outcome measures: Three-year cost of therapy when considering medication as well as travel costs and time spent in transit. Results: Based on cost data derived purely from wholesale acquisition cost and projected injection frequency over the first three years of treatment, faricimab is less expensive than ranibizumab and aflibercept by $37,709 and $6359, respectively. Aflibercept is less expensive ranibizumab by $31,350 over the first 3 years of treatment. When considering even small distances traveled by patients, these cost differences grow, amplified at even larger distances: at 25 miles, ranibizumab becomes $38,814 and $32,133 more expensive than faricimab and aflibercept, respectively. Aflibercept becomes $6681 more expensive than faricimab. At 100 miles, ranibizumab becomes $41,502 and $34,038 more expensive than faricimab and aflibercept, respectively. Aflibercept becomes $7464 more expensive than faricimab. Conclusion: Longer acting anti-VEGF therapies may differ not only in their wholesale acquisition cost, but also in the frequency of per label injections and associated clinic visits. Taking into account distance and time cost of travel may contribute to a more holistic view of cost differences among these therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/opth.s384995

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 6

  1. Rosenfeld, 2006, N Engl J Med, 355, 1419, 10.1056/NEJMOA054481/SUPPL_FILE/NEJM_ROSENFELD_SA1.PDF · doi:10.1056/nejmoa054481/suppl_file/nejm_rosenfeld_sa1.pdf
  2. Khanani, 2021, Invest Ophthalmol Vis Sci, 62, 428
  3. Li, 2020, Cochrane Database Syst Rev, 2020, 10.1002/14651858.CD012208.PUB2/MEDIA/CDSR/CD012208/IMAGE_N/NCD012208-CMP-004.03.SVG · doi:10.1002/14651858.cd012208.pub2/media/cdsr/cd012208/image_n/ncd012208-cmp-004.03.svg
  4. 2016, Cost-Effectiveness in Health and Medicine
  5. Ray, 2015, Am J Manag Care, 21, 567
  6. Gelfand, 2021, Front Psychol, 12, 3785, 10.3389/FPSYG.2021.727871/BIBTEX · doi:10.3389/fpsyg.2021.727871/bibtex

Cited by

See all 21

Metadata

Authors
Meer, E. A., Oh, D. H., & Brodie, F. L.
Affiliations
  • University of California, San Francisco (US)
  • San Francisco VA Medical Center (US)
Corresponding author
Brodie, Frank L
Venue
Clinical Ophthalmology
Published
2022-12
Volume
Volume 16
Pages
4273-4279
ISSN
  • 1177-5467 (ISSN-L)
  • 1177-5483
OpenAlex
W4312070261
Cited by
21
References
32
Citations by year
2026: 4 · 2025: 7 · 2024: 4 · 2023: 6
FWCI
3.80
Type
journal article
Language
en
Open access
Locations
  • Clinical ophthalmology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
age-related macular degeneration, anti-VEGF therapy, faricimab, ranibizumab, aflibercept, drug cost comparison, travel cost, time costs, clinic visits, Veterans Affairs hospitals, wholesale acquisition cost, injection frequency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons. https://app.cochat.ai/papers/10.2147/opth.s384995
The paper
Meer, E. A., Oh, D. H., & Brodie, F. L. (2022). Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons. Clinical Ophthalmology. https://doi.org/10.2147/opth.s384995

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.